Background. Curcumin (CUR), a natural phenolic compound, has been recently reported to exert antitumor actions in variety of cancers; however, the exact mechanism(s) is not clear. In this study we investigated whether CUR could inhibit Ras/MAPK pathway and enhance mitomycin C (MMC) cytotoxicity in T24 bladder cancer cells. Methods. T24 cells were cultured with different concentrations of CUR (5, 10, 20 μM) alone or combined with 10 μg/ml MMC. At the end of 72 h culture, cell viability was assessed by MTT assay; apoptosis by flow cytometry; total Ras and ERK1/2 by immunohistochemistry and western blotting. Results. In comparison to cells exposed to MMC alone, cells treated with combined MMC and either 10 or 20 μM CUR showed reduced cell proliferation, disrupted morphological appearance, and increased subG0/G1 apoptotic events. This inhibition was associated with marked reduction of Ras and ERK1/2 expression. Likewise, cells treated with 10 or 20 μM CUR alone showed significant inhibition, while the effect of 5 μM was less obvious. Conclusion. Resistance of T24 cells to cytotoxic effect of MMC is dependent, at least partially, on Ras/ERK activation. CUR at concentrations of 10 and 20 μM in combination with low dose MMC induced toxic synergism in T24 cells. Clinical translation of this experimental study may be reasonable in light of wide safety margin and availability of CUR.
INTRODUCTION
Despite the advancement in cancer therapy, bladder cancer remains one of the major challenges leading to worldwide cancer-related death [1] . The initial treatment of non-muscle-invasive transitional cell carcinoma of the bladder generally is a complete cystoscopic resection of all visible tumour followed by adjuvant intravesical therapy [2] . Mitomycin C (MMC) is one of the most commonly used intravesical chemotherapeutic agents although its clinical effectiveness is often limited by high rate of recurrence due to the emergence of drug-resistant tumour cells [3] [4] . So, multiple approaches have been tried to improve efficacy and decrease recurrence including increasing the drug concentration and extending the dwell time [5] .
Sufficient body of evidence has recognized the association between bladder cancer, as well as resistance to chemotherapy, and the production of abnormal signal transducer Ras protein [6] . This association has been early reported in T24 bladder cancer cell line where the first human oncogene was identified [7] . Mutations in RAS genes can direct the expression of constitutively active Ras proteins which promote the activation of the immediate effector Raf kinase family.
Once activated, Raf initiates the sequential downstream 40 phosphorylation of MEK and ERK which finally interact with transcription factors responsible for cell cycle progression and proliferation. Locked in the GTP-bound mode, the abnormally activated Ras protein triggers incessant activation of the Raf/MEK/ERK cascade leading to uninterrupted cell division and carcinogenesis [8] [9] . Overexpression of at least 1 of the 3 canonical Ras proteins was found in 77% of analyzed bladder tumours [10] while even a single nucleotide polymorphism in the H-Ras locus was associated with development of more aggressive types of bladder cancer [11] . Ras inhibition was employed as a treatment strategy to control cell proliferation, to induce apoptosis and to increase the sensitivity of tumour cells to different tumour cell-killing agents. The inhibition was targeted at many levels of the Ras/ MAPK signaling circuit [12] [13] .
Curcumin (CUR) is the principal polyphenolic compound (Fig 1) isolated from the powdered rhizome of turmeric (Curcuma longa L.), a member of the ginger family.
Although several research point at curcumin as having wide range of pharmacological activities but clinical studies have yielded frustrating results due to its chemical instability and poor oral bioavailability [14] , however, recent reports demonstrated promising anti-tumour effects of curcumin against variable types of cancer cells in vitro [15] . The precise target(s) of curcumin action have remained elusive with some reports described its interaction with several signal transduction pathways including NF-κB, AKT, Ras/MAPK, p53, JAK/STAT and AMPK [16] . Recent observation has also shown that modulation of cell signaling pathways through the pleiotropic effects of curcumin likely activate cell death signals and induce apoptosis predominantly in Ras-activated tumour cells [17] . On the other hand, we have recently shown that silencing the RAS oncogene by small interfering RNA (siRNA) reversed the resistance of T24 bladder cancer cells to MMC and induced apoptosis when exposed to small doses of MMC (0.3 to 10 µg/ml) [18] . Based on this finding and other related experiments demonstrating that inhibition of Ras decreased resistance and invasiveness of cancer cells in vitro, if curcumin can disrupt the Ras/Raf/MEK/ERK signaling pathway, it should reverse Ras-dependent resistance of cancer cells to chemotherapeutic agents. Therefore, we aimed at investigating the combined effect of curcumin with small dose of MMC on the Ras/MAPK-dependent apoptosis in T24 bladder cancer cells which were reported earlier to be naturally resistant to MMC [19] . We hypothesise that curcumin may induce synergistic tumor cell killing with MMC comparable to that previously observed with Ras siRNA, consequently, curcumin might be elected as a safe and available intravesical adjuvant with MMC in clinical trials.
MATERIALS AND METHODS

Cell culture
Human bladder cancer cell line T24, obtained from the European Collection of Authenticated Cell Cultures (ECACC), were grown in confluent monolayers with McCoy's 5A medium (Sigma-Aldrich Co. Ltd., Poole, Dorset, England) supplemented with 10% fetal calf serum (FCS), 100 U/ml penicillin and 100 µg/ml streptomycin, and maintained at 37 °C with 5% CO2. Under these conditions the doubling time was A full set of controls were used to detect false negative and false positive results. The final concentration of DMSO for all experiments was maintained at less than 0.1%. These concentrations were previously reported to be non-cytotoxic for 72 h [17] .
Treatment protocols
Cell proliferation assay
The anti-proliferative potential of treatments was assessed by 
Immunocytochemistry (ICC)
Alcohol-fixed cells were washed prior to immunostaining using 5 µg/ml of anti-pan-Ras (clone Ras10, Upstate, VA, USA) and 1 µg/ml of mouse polyclonal ERK which reacts with both ERK1/2 (Santa-Cruz Biotechnology, Santa-Cruz, CA) or matched isotypes IgG2a (Ras) and IgG1 (ERK) at equivalent concentrations diluted in PBS with 0.04% Tween 80 (PBST). Immunoreactivity was visualised using HRP Mouse (DAB+) EnVision Kit (Dako). Computer-aided quantification of ICC staining was performed based on the principle described before [21] with slight modification [22] .
Briefly, digital images were acquired at X100 using Leica dig- 
Western blotting
After trypsinization and centrifugation, washed cell pellets were lysed for 15 min on ice using 300 µl of CelLytic-M mammalian reagent (Sigma-Aldrich, UK) followed by centrifugation at 15,000 x g for 20 min at 4 °C. Soluble protein concentration in the supernatant was determined using Pierce BCA Protein Assay kit and instructions (Thermo Scientific, USA). Aliquots of 15 μg of denaturated and reduced protein were resolved on NuPAGE Novex 4-12% Bis-Tris Gels (Invitrogen, USA) by SDS-PAGE prior to transfer onto nitrocellulose membrane (Bio-Rad Lab., USA). After incubation in blocking buffer (5% non-fat milk in TBST) for 2 h at room temperature, membranes were incubated overnight at 4 °C with mouse monoclonal antibodies (Santa Cruz Biotech., Santa Cruz, CA, USA) against pan-Ras, pERK1/2, 42 and β-actin followed by incubation with horseradish peroxidase-conjugated secondary anti-mouse IgG (1:1000; Santa-Cruz) for 1 h at room temperature. After three washes in PBS with 0.1% Tween-20, Images were digitized using ViewPix 700 gel scanner and analyzed by TotalLab software (TotalLab Ltd. UK).
Statistical analysis
The statistical analysis was performed using SPSS 15.0 (SPSS Inc., Chicago, IL, USA). Data were quantified from triplicate measurements and were represented as mean ± SD. Multiple comparison between means was performed using the oneway analysis of variance (ANOVA) followed by Tukey post hoc test. A P-value of less than 0.05 was considered statistically significant. Fig 2) . Cell proliferation assay revealed 38% reduction of cell viability after exposure to 10 µg/ml MMC.
RESULTS
T24 cells sensitivity after single MMC or curcumin treatment
There was also dese-dependent reduction of cell viability with 10 and 20 µM curcumin alone (P<0.05, Fig 3) . (Fig 5 and 6 ). Ras and ERK1/2 immunostaining showed progressive decrease with the maximum inhibition seen with 20 µM dose of curcumin (10.31 ± 2.42 and 8.37 ± 2.11 respectively in MMC plus curcumin compared to 17.49% ± 3.42 and 14.81% ± 3.02 in MMC alone, P<0.05 for both). Western blot studies also confirmed these results (Fig 7) . tendency to develop tumor invasiveness and resistance [23] .
It is now established that activated Ras-GTP triggers mitogenic signaling and ultimately leading to activation of transcriptional ERKs [24] . The activated Ras/Raf/ERK-signaling pathway creates a robust proliferative stimulus that leads to uncontrolled cell division [25] [26] . In a previous study [18] , we have shown that knocking down the Ras oncogene resulted in enhanced MMC-induced chemosensitivity and apoptosis in T24 cells which has been previously reported to be MMC-resistant [19] .
Conclusion of synergism between drug combinations
should be investigated carefully. Ideal synergism should involve positive interaction between the two drugs on one common target by exerting different mechanisms of action.
Alkylation of DNA is the most favoured mechanism of action for MMC, but other modes of action, such as inhibition of rRNA and redox cycle interference, may also contribute to the biological action of the drug [27] . The understanding of the appropriate dose and duration of MMC exposure was acquired from our previous study which proved that MMC treatment using low concentrations over 72 h was the best combination regimen with Ras siRNA. This pre-rationale assessment strategy meant that the siRNA treatment protocol was based on a substantial background and information of how the proteins worked in response to individual agents.
This was particularly important because the "hit" of the second therapy could be scheduled to coincide with the lowest expression of the target. Data presented herein have shown that T24 cells express more Ras, supporting previous reports that Ras expression was associated with tumor cell resistance [28] . We observed that both Ras and ERK1/2 immunoreactivity in T24 cells was decreased 72h after treatment with MMC, and this could be perceived in light of depletion of the protein synthesis capacity in T24 cells after 72h. These data suggest that Ras siRNA would be most effective 72h after treatment with low concentrations of MMC.
In our previous study [18] , we used MMC in low and high concentrations (up to 100 μg/ml) in combination with two different concentrations of Ras siRNA, and we found that Ras siRNA sensitized T24 cells to apoptosis induced by in cervical cancer cells [29] , breast cancer cells [30] , and reduces multidrug resistance in human colon cancer cells [31] .
However, the exact mechanism and/or molecular targets of curcumin remain elusive. So, we hypothesized that curcum- 
